Drug or treatment
Tunlametinib clinical trials
As of November 12, 2026, Find a Trial lists 5 clinical trials of Tunlametinib that are recruiting, in China. By phase: Phase 2 (3), Phase 4 (1), Phase 3 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 1Country
Newest trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Combo of tunlametinib, pucotenlimab, and hydroxychloroquine in NRAS-mutant melanoma | Phase 2 | Guangzhou, Guangdong | Recruiting | Aug 6, 2026 |
| Tunlametinib for NRAS‑mutant advanced melanoma after PD‑1/PD‑L1 therapy | Phase 4 | Shanghai | Recruiting | Mar 3, 2026 |
| Tunlametinib for NRAS‑mutant non‑melanoma refractory solid tumors | Phase 2 | Tianjin, Tianjin Municipality | Recruiting | Sep 12, 2025 |
| Tunlametinib for advanced NRAS‑mutant thyroid cancer | Phase 2 | Shanghai, Shanghai Municipality | Recruiting | May 14, 2025 |
| Comparing tunlametinib capsules with chemotherapy for advanced NRAS-mutant melanoma | Phase 3 | Beijing, Beijing Municipality | Recruiting | Aug 23, 2023 |
All recruiting trials (5)
-
Combo of tunlametinib, pucotenlimab, and hydroxychloroquine in NRAS-mutant melanoma
This study tests whether adding hydroxychloroquine to tunlametinib and pucotenlimab helps people with NRAS-mutant melanoma.
-
Tunlametinib for NRAS‑mutant advanced melanoma after PD‑1/PD‑L1 therapy
This study will test whether the oral drug tunlametinib helps adults with NRAS‑mutant advanced melanoma who did not respond to anti‑PD‑1/PD‑L1 therapy.
-
Tunlametinib for NRAS‑mutant non‑melanoma refractory solid tumors
This trial tests tunlametinib to see if it can shrink or control advanced non‑melanoma solid tumors that have NRAS mutations in patients who have failed standard treatments.
-
Tunlametinib for advanced NRAS‑mutant thyroid cancer
This trial tests whether the MEK inhibitor tunlametinib, alone or with a PD‑1 immunotherapy, can shrink or control tumors in adults with advanced NRAS‑mutant thyroid cancer that is refractory to radioactive iodine.
-
Comparing tunlametinib capsules with chemotherapy for advanced NRAS-mutant melanoma
This study is testing if tunlametinib capsules can work better than standard chemotherapy for people with advanced melanoma that has NRAS mutations and who have already tried immunotherapy.
Quick answers
How many clinical trials of Tunlametinib are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
All of them have sites in China. Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 3, Phase 4: 1, Phase 3: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.